{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:45:23Z","timestamp":1793997923376,"version":"4.8.0"},"reference-count":371,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.4158\/gl-2020-0524suppl","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T17:42:16Z","timestamp":1589910136000},"page":"1-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1101,"special_numbering":"S1","title":["American Association of Clinical Endocrinologists\/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis\u20142020 Update"],"prefix":"10.1016","volume":"26","author":[{"given":"Pauline M.","family":"Camacho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Petak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Binkley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dima L.","family":"Diab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie S.","family":"Eldeiry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azeez","family":"Farooki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven T.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Hurley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Michael","family":"Lewiecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Pessah-Pollack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"McClung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil J.","family":"Wimalawansa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson B.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4158\/GL-2020-0524SUPPL_bb0005","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.4158\/EP171866.GL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology protocol for standardized prodcution of clinical practice guidelines, algorithms, and checklists -- 2017 update","volume":"23","author":"Mechanick","year":"2017","journal-title":"Endocr Pract."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0010","doi-asserted-by":"crossref","first-page":"692","DOI":"10.4158\/EP14166.PS","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology protocol for standardized production of clinical practice guidelines, algorithms, and checklists--2014 update and the AACE G4G program","volume":"20","author":"Mechanick","year":"2014","journal-title":"Endocr Pract."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0015","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4158\/EP.16.2.270","article-title":"American Association of Clinical Endocrinologists protocol for standardized production of clinical practice guidelines--2010 update","volume":"16","author":"Mechanick","year":"2010","journal-title":"Endocr Pract."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0020","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4158\/EP.10.4.353","article-title":"American Association of Clinical Endocrinologists protocol for standardized production of clinical practice guidelines","volume":"10","author":"Mechanick","year":"2004","journal-title":"Endocr Pract."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0025","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1002\/jbmr.2269","article-title":"The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine","volume":"29","author":"Wright","year":"2014","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0030","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1359\/jbmr.061113","article-title":"Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025","volume":"22","author":"Burge","year":"2007","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0035","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","article-title":"The diagnosis of osteoporosis","volume":"9","author":"Kanis","year":"1994","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0040","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.mayocp.2014.09.011","article-title":"Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States","volume":"90","author":"Singer","year":"2015","journal-title":"Mayo Clin Proc."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0045","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1359\/jbmr.1997.12.11.1761","article-title":"Prevalence of low femoral bone density in older U.S. adults from NHANES III","volume":"12","author":"Looker","year":"1997","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0050","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1385\/JCD:2:3:343","article-title":"Discordance in patient classification using T-scores","volume":"2","author":"Faulkner","year":"1999","journal-title":"J Clin Densitom."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0055","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF01623271","article-title":"Prevalence and incidence of vertebral deformities","volume":"3","author":"Melton","year":"1993","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0060","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.4158\/GL-2020-0524SUPPL_bb0065","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1148\/rg.315105712","article-title":"Integrated imaging approach to osteoporosis: state-of-the-art review and update","volume":"31","author":"Guglielmi","year":"2011","journal-title":"Radiographics."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0070","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00198-011-1592-3","article-title":"High fracture probability with FRAX usually indicates densitometric osteoporosis: implications for clinical practice","volume":"23","author":"Leslie","year":"2012","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0075","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s00198-014-2655-z","article-title":"The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group","volume":"25","author":"Siris","year":"2014","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0080","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1007\/s00198-012-1991-0","article-title":"What\u2019s in a name? What constitutes the clinical diagnosis of osteoporosis?","volume":"23","author":"Siris","year":"2012","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0085","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1210\/jc.2004-1568","article-title":"Hip fracture in women without osteoporosis","volume":"90","author":"Wainwright","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0090","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00198-009-1007-x","article-title":"Population screening for osteoporosis risk: a randomised control trial of medication use and fracture risk","volume":"21","author":"Barr","year":"2010","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0095","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1524-4733.2009.00687.x","article-title":"Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence","volume":"13","author":"Hiligsmann","year":"2010","journal-title":"Value Health."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0100","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/0017896910364570","article-title":"Health beliefs about osteoporosis and osteoporosis screening in older women and men","volume":"69","author":"Nayak","year":"2010","journal-title":"Health Educ J."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0105","doi-asserted-by":"crossref","first-page":"99","DOI":"10.7326\/0003-4819-153-2-201007200-00262","article-title":"Screening for osteoporosis: an update for the U.S. Preventive Services Task Force","volume":"153","author":"Nelson","year":"2010","journal-title":"Ann Intern Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0110","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jht.2009.11.001","article-title":"Screening for falls and osteoporosis: prevention practice for the hand therapist","volume":"23","author":"Thompson","year":"2010","journal-title":"J Hand Ther."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0115","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00198-017-4326-3","article-title":"Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study","volume":"29","author":"Rubin","year":"2018","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0120","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(17)32640-5","article-title":"Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial","volume":"391","author":"Shepstone","year":"2018","journal-title":"Lancet."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0125","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2018.6537","article-title":"Screening to prevent osteoporotic fractures: updated evidence report and systematic review for the US Preventive Services Task Force","volume":"319","author":"Viswanathan","year":"2018","journal-title":"JAMA."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0130","series-title":"Assessment of osteoporosis at the primary health care level","article-title":"WHO Collaborating Center for Metabolic Bone Disease Technical Report","author":"Kanis","year":"2008"},{"key":"10.4158\/GL-2020-0524SUPPL_bb0135","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ocl.2006.08.003","article-title":"Hip fracture and its consequences: differences between men and women","volume":"37","author":"Orwig","year":"2006","journal-title":"Orthop Clin North Am."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0140","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1007\/s00198-011-1713-z","article-title":"Interpretation and use of FRAX in clinical practice","volume":"22","author":"Kanis","year":"2011","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0145","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jocd.2011.05.018","article-title":"FRAX\u00ae Bone Mineral Density Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation position development conference","volume":"14","author":"Lewiecki","year":"2011","journal-title":"J Clin Densitom."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0150","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11657-013-0166-8","article-title":"Worldwide uptake of FRAX","volume":"9","author":"Kanis","year":"2014","journal-title":"Arch Osteoporos."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00223-011-9544-7","article-title":"FRAX\u00ae with and without bone mineral density","volume":"90","author":"Kanis","year":"2012","journal-title":"Calcif Tissue Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0160","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1002\/jbmr.372","article-title":"WHO absolute fracture risk models (FRAX): do clinical risk factors improve fracture prediction in older women without osteoporosis?","volume":"26","author":"Hillier","year":"2011","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0165","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/s001980200084","article-title":"Does a fracture at one site predict later fractures at other sites? A British cohort study","volume":"13","author":"van Staa","year":"2002","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0170","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/jbmr.1476","article-title":"Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women","volume":"27","author":"Gehlbach","year":"2012","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0175","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jama.285.3.320","article-title":"Risk of new vertebral fracture in the year following a fracture","volume":"285","author":"Lindsay","year":"2001","journal-title":"JAMA."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0180","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1359\/JBMR.050304","article-title":"Predictive value of BMD for hip and other fractures","volume":"20","author":"Johnell","year":"2005","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0185","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/BOR.0b013e328356d2f5","article-title":"FRAX updates 2012","volume":"24","author":"McCloskey","year":"2012","journal-title":"Curr Opin Rheumatol."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0190","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s11914-010-0032-1","article-title":"The utility and limitations of FRAX: A US perspective","volume":"8","author":"Silverman","year":"2010","journal-title":"Curr Osteoporos Rep."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0195","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1359\/jbmr.090402","article-title":"FRAX facts","volume":"24","author":"Watts","year":"2009","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0200","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s11914-010-0022-3","article-title":"Assessment of individual fracture risk: FRAX and beyond","volume":"8","author":"van den Bergh","year":"2010","journal-title":"Curr Osteoporos Rep."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0205","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bone.2014.01.014","article-title":"Impact of changes in mortality on FRAX-derived fracture probabilities","volume":"62","author":"Kreidieh","year":"2014","journal-title":"Bone."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0210","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00198-010-1524-7","article-title":"Guidance for the adjustment of FRAX according to the dose of glucocorticoids","volume":"22","author":"Kanis","year":"2011","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0215","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00198-010-1461-5","article-title":"Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement","volume":"22","author":"Leslie","year":"2011","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0220","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/jbmr.1582","article-title":"Does osteoporosis therapy invalidate FRAX for fracture prediction?","volume":"27","author":"Leslie","year":"2012","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0225","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00198-006-0290-z","article-title":"Influence of fall related factors and bone strength on fracture risk in the frail elderly","volume":"18","author":"Sambrook","year":"2007","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0230","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00198-007-0343-y","article-title":"The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women","volume":"18","author":"Kanis","year":"2007","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0240","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1359\/jbmr.2003.18.11.1947","article-title":"BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures","volume":"18","author":"Stone","year":"2003","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0245","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/0140-6736(93)92555-8","article-title":"Bone density at various sites for prediction of hip fractures. The study of osteoporotic fractures research group","volume":"341","author":"Cummings","year":"1993","journal-title":"Lancet."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0250","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/jbmr.5650070607","article-title":"Axial and appendicular bone density predict fractures in older women","volume":"7","author":"Black","year":"1992","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0255","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bmj.312.7041.1254","article-title":"Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures","volume":"312","author":"Marshall","year":"1996","journal-title":"BMJ."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0260","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/jbmr.1472","article-title":"Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures","volume":"27","author":"Austin","year":"2012","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0265","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.bone.2007.11.018","article-title":"Correlations between grey-level variations in 2D projection images (TBS) and 3D microarchtecture: applications in the study of human trabecular bone microarchitecture","volume":"42","author":"Pothuaud","year":"2008","journal-title":"Bone."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0270","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/jbmr.2176","article-title":"Trabecular bone score: a noninvasive analytical method based upon the DXA image","volume":"29","author":"Silva","year":"2014","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0275","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.bone.2015.05.016","article-title":"Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice","volume":"78","author":"Harvey","year":"2015","journal-title":"Bone."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0280","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/jbmr.2734","article-title":"A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX","volume":"31","author":"McCloskey","year":"2016","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0285","doi-asserted-by":"crossref","first-page":"220","DOI":"10.4158\/CS-2017-0081","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the quality of DXA scans and reports","volume":"24","author":"Licata","year":"2018","journal-title":"Endocr Pract."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0290","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jocd.2016.03.003","article-title":"Best practices for dual-energy X-ray absorptiometry measurement and reporting: International Society for Clinical Densitometry Guidance","volume":"19","author":"Lewiecki","year":"2016","journal-title":"J Clin Densitom."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0295","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nrendo.2010.86","article-title":"Bone: is screening for secondary causes of osteoporosis worthwhile?","volume":"6","author":"Gallagher","year":"2010","journal-title":"Nat Rev Endocrinol."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0300","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1210\/jc.2002-021660","article-title":"Recommended testing in patients with low bone density","volume":"88","author":"Barzel","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0305","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1210\/jc.2002-020275","article-title":"Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women","volume":"87","author":"Tannenbaum","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0310","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/BLO.0b013e3180534269","article-title":"Prior fractures are common in patients with subsequent hip fractures","volume":"461","author":"Edwards","year":"2007","journal-title":"Clin Orthop Relat Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0315","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1200\/JCO.2008.17.7451","article-title":"Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis","volume":"26","author":"Camacho","year":"2008","journal-title":"J Clin Oncol."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0320","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0889-857X(05)70196-4","article-title":"An update on glucocorticoid-induced osteoporosis","volume":"27","author":"Lane","year":"2001","journal-title":"Rheum Dis Clin North Am."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0325","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1210\/jc.2006-1178","article-title":"Clinical review: Clinical applications of vertebral fracture assessment by dual-energy X-ray absorptiometry","volume":"91","author":"Lewiecki","year":"2006","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0330","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1385\/JCD:4:4:373","article-title":"Instant vertebral assessment: a noninvasive dual X-ray absorptiometry technique to avoid misclassification and clinical mismanagement of osteoporosis","volume":"4","author":"Greenspan","year":"2001","journal-title":"J Clin Densitom."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0335","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00198-005-2010-5","article-title":"Reliability and accuracy of vertebral fracture assessment with densitometry compared to radiography in clinical practice","volume":"17","author":"Schousboe","year":"2006","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0340","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s00198-005-1891-7","article-title":"Lateral vertebral assessment: a valuable technique to detect clinically significant vertebral fractures","volume":"16","author":"Binkley","year":"2005","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0345","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00198-004-1709-z","article-title":"Accuracy of height loss during prospective monitoring for detection of incident vertebral fractures","volume":"16","author":"Siminoski","year":"2005","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0350","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00198-005-2017-y","article-title":"The accuracy of historical height loss for the detection of vertebral fractures in postmenopausal women","volume":"17","author":"Siminoski","year":"2006","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0355","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0002-9343(96)00387-7","article-title":"Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density","volume":"102","author":"Chesnut","year":"1997","journal-title":"Am J Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0360","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1359\/jbmr.1998.13.2.297","article-title":"Rapid bone loss is associated with increased levels of biochemical markers","volume":"13","author":"Ross","year":"1998","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0365","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1359\/jbmr.1999.14.9.1614","article-title":"Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study","volume":"14","author":"Garnero","year":"1999","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0370","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/jbmr.5650111021","article-title":"Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study","volume":"11","author":"Garnero","year":"1996","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0375","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1359\/jbmr.2000.15.8.1526","article-title":"Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study","volume":"15","author":"Garnero","year":"2000","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0380","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","article-title":"Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards","volume":"22","author":"Vasikaran","year":"2011","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0385","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/jbmr.3471","article-title":"Bone turnover markers are not associated with hip fracture risk: a case-control study in the Woment\u2019s Health Initiative","volume":"33","author":"Crandall","year":"2018","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0390","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate","volume":"18","author":"Eastell","year":"2003","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0395","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1359\/JBMR.040512","article-title":"Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the Fracture Intervention Trial","volume":"19","author":"Bauer","year":"2004","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0400","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00198-015-3145-7","article-title":"Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study","volume":"27","author":"Naylor","year":"2016","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0405","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.bone.2009.07.091","article-title":"Rapid and robust response of biochemical markers of bone formation to teriparatide therapy","volume":"45","author":"Glover","year":"2009","journal-title":"Bone."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0410","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1002\/jbmr.342","article-title":"Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence","volume":"26","author":"Eastell","year":"2011","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0415","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/jbmr.251","article-title":"Effects of denosumab on bone turnover markers in postmenopausal osteoporosis","volume":"26","author":"Eastell","year":"2011","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0420","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1007\/s00198-012-2049-z","article-title":"National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges","volume":"23","author":"Bauer","year":"2012","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0425","first-page":"373","article-title":"Use of CTX-I and PINP as bone turnover markers: Nationall Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability","volume":"76","author":"Szulc","year":"2018","journal-title":"Ann Biol Clin (Paris)."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0430","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1210\/jc.2004-1091","volume":"90","author":"Greenspan","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0435","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1210\/jc.2005-1712","article-title":"Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis","volume":"91","author":"Bauer","year":"2006","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0440","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jcem.87.4.8415","article-title":"Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents","volume":"87","author":"Hochberg","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0445","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1001\/jamainternmed.2014.1232","article-title":"Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study","volume":"174","author":"Bauer","year":"2014","journal-title":"JAMA Intern Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0450","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1007\/s00198-011-1868-7","article-title":"The 25(OH)D level needed to maintain a favorable bisphosphonate response is \u226533 ng\/ ml","volume":"23","author":"Carmel","year":"2012","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0455","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.amjmed.2003.12.029","article-title":"Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults","volume":"116","author":"Bischoff-Ferrari","year":"2004","journal-title":"Am J Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0460","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1017\/S1368980011000565","article-title":"The 2011 report on dietary reference intakes for calcium and vitamin D","volume":"14","author":"Ross","year":"2011","journal-title":"Public Health Nutr."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0465","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1210\/jc.2011-0385","article-title":"Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline","volume":"96","author":"Holick","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0470","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1210\/jc.2004-2364","article-title":"Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy","volume":"90","author":"Holick","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0475","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s00198-008-0582-6","article-title":"Vitamin D-deficiency and post-fracture changes in lower extremity function and falls in women with hip fractures","volume":"19","author":"LeBoff","year":"2008","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0480","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11914-011-0094-8","article-title":"Vitamin D in the new millennium","volume":"10","author":"Wimalawansa","year":"2012","journal-title":"Curr Osteoporos Rep."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0485","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jsbmb.2016.09.016","article-title":"Non-musculoskeletal benefits of vitamin D","volume":"175","author":"Wimalawansa","year":"2018","journal-title":"J Steroid Biochem Mol Biol."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0490","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1500409","article-title":"A trial of calcium and vitamin D for the prevention of colorectal adenomas","volume":"373","author":"Baron","year":"2015","journal-title":"N Engl J Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0495","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1161\/CIRCULATIONAHA.114.011732","article-title":"Vitamin D therapy in individuals with prehypertension or hypertension: the DAYLIGHT trial","volume":"131","author":"Arora","year":"2015","journal-title":"Circulation."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0500","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3945\/ajcn.113.073734","article-title":"Vitamin D3 supplementation during weight loss: a double-blind randomized controlled trial","volume":"99","author":"Mason","year":"2014","journal-title":"Am J Clin Nutr."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0505","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.4158\/EP13518.OR","article-title":"The vitamin d dose response in obesity","volume":"20","author":"Dhaliwal","year":"2014","journal-title":"Endocr Pract."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0510","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1210\/jc.2013-2647","article-title":"Does vitamin D improve muscle strength in adults? A randomized, double-blind, placebo-controlled trial among ethnic minorities in Norway","volume":"99","author":"Knutsen","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0515","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4158\/EP14416.OR","article-title":"Effectiveness and outcomes of current practice in treating vitamin D deficiency in patients listed for liver transplantation","volume":"21","author":"Chaney","year":"2015","journal-title":"Endocr Pract."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0520","doi-asserted-by":"crossref","first-page":"122","DOI":"10.4158\/EP14320.OR","article-title":"Ethnicity, clothing style, and body mass index are significant predictors of vitamin D insufficiency in Germany","volume":"21","author":"Farahati","year":"2015","journal-title":"Endocr Pract."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0525","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4158\/EP14123.OR","article-title":"Vitamin D, parathyroid hormone, and heart failure in a Chinese elderly population","volume":"21","author":"Li","year":"2015","journal-title":"Endocr Pract."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0530","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s001980050030","article-title":"Prevalence of vitamin D insufficiency in an adult normal population","volume":"7","author":"Chapuy","year":"1997","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0535","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1210\/jc.2006-1404","article-title":"Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trials","volume":"92","author":"Boonen","year":"2007","journal-title":"J Clin Endocrinol Metab."},{"issue":"suppl 4","key":"10.4158\/GL-2020-0524SUPPL_bb0540","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP161435.GL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2016","volume":"22","author":"Camacho","year":"2016","journal-title":"Endocr Pract."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0545","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1210\/jc.2010-2704","article-title":"The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know","volume":"96","author":"Ross","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0550","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMp1608005","article-title":"Vitamin D deficiency-is there really a pandemic?","volume":"375","author":"Manson","year":"2016","journal-title":"N Engl J Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0555","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1001\/jamainternmed.2015.3874","article-title":"Treatment of vitamin D insufficiency in postmenopausal women: a randomized clinical trial","volume":"175","author":"Hansen","year":"2015","journal-title":"JAMA Intern Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0560","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000450766","article-title":"Use of extended-release calcifediol to treat secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease","volume":"44","author":"Sprague","year":"2016","journal-title":"Am J Nephrol."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0565","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1001\/jama.293.18.2257","article-title":"Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials","volume":"293","author":"Bischoff-Ferrari","year":"2005","journal-title":"JAMA."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0570","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJMoa055218","article-title":"Calcium plus vitamin D supplementation and the risk of fractures","volume":"354","author":"Jackson","year":"2006","journal-title":"N Engl J Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0575","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1007\/s00198-005-0030-9","article-title":"Is fall prevention by vitamin D mediated by a change in postural or dynamic balance?","volume":"17","author":"Bischoff-Ferrari","year":"2006","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0580","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1359\/jbmr.2000.15.6.1113","article-title":"Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women","volume":"15","author":"Pfeifer","year":"2000","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0585","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1001\/archinte.167.16.1730","article-title":"Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials","volume":"167","author":"Autier","year":"2007","journal-title":"Arch Intern Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0590","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jamainternmed.2015.7148","article-title":"Monthly high-dose vitamin D treatment for the prevention of functional decline: a randomized clinical trial","volume":"176","author":"Bischoff-Ferrari","year":"2016","journal-title":"JAMA Intern Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0595","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1001\/jama.2010.594","article-title":"Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial","volume":"303","author":"Sanders","year":"2010","journal-title":"JAMA."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0600","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/nutrit\/nuu004","article-title":"Quantifying the vitamin D economy","volume":"73","author":"Heaney","year":"2015","journal-title":"Nutr Rev."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0605","first-page":"3675","article-title":"How to optimize vitamin D supplementation to prevent cancer, based on cellular adaptation and hydroxylase enzymology","volume":"29","author":"Vieth","year":"2009","journal-title":"Anticancer Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0610","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.bone.2018.02.024","article-title":"Comparison of the effect of daily versus bolus dose maternal vitamin D3 supplementation on the 24,25-dihydroxyvitamin D3 25-hydroxyvitamin D3 ratio","volume":"110","author":"Ketha","year":"2018","journal-title":"Bone."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0615","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.4158\/EP-2018-0415","article-title":"It\u2019s time to stop prescribing ergocalciferol","volume":"24","author":"Binkley","year":"2018","journal-title":"Endocr Pract."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0620","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1373\/jalm.2017.024323","article-title":"Price of high-throughput 25-hydroxyvitamin D immunoassays: frequency of inaccurate results","volume":"2","author":"Tolan","year":"2018","journal-title":"J Appl Lab Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0625","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.clinbiochem.2015.08.005","article-title":"Performance characteristics of six automated 25-hydroxyvitamin D assays: mind your 3s and 2s","volume":"48","author":"Wyness","year":"2015","journal-title":"Clin Biochem."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0630","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00198-015-3386-5","article-title":"Calcium plus vitamin D supplementation and risk of fractures: an updated metaanalysis from the National Osteoporosis Foundation","volume":"27","author":"Weaver","year":"2016","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0635","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/bmj.330.7498.1003","article-title":"Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care","volume":"330","author":"Porthouse","year":"2005","journal-title":"BMJ."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0640","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1210\/er.2001-7002","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis","volume":"23","author":"Shea","year":"2002","journal-title":"Endocr Rev."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0645","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/S0140-6736(05)63013-9","article-title":"Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial","volume":"365","author":"Grant","year":"2005","journal-title":"Lancet."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0650","doi-asserted-by":"crossref","first-page":"f228","DOI":"10.1136\/bmj.f228","article-title":"Long term calcium intake and rates of all cause and cardiovascular mortality: community based prospective longitudinal cohort study","volume":"346","author":"Micha\u00eblsson","year":"2013","journal-title":"BMJ."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0655","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/bmj.39440.525752.BE","article-title":"Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial","volume":"336","author":"Bolland","year":"2008","journal-title":"BMJ."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0660","doi-asserted-by":"crossref","first-page":"c3691","DOI":"10.1136\/bmj.c3691","article-title":"Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis","volume":"341","author":"Bolland","year":"2010","journal-title":"BMJ."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0665","doi-asserted-by":"crossref","first-page":"d2040","DOI":"10.1136\/bmj.d2040","article-title":"Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women\u2019s Health Initiative limited access dataset and meta-analysis","volume":"342","author":"Bolland","year":"2011","journal-title":"BMJ."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0670","doi-asserted-by":"crossref","first-page":"190","DOI":"10.7326\/M19-0341","article-title":"Effects of nutritional supplements and dietary intervention on cardiovascular outcomes: an umbrella review and evidence map","volume":"171","author":"Khan","year":"2019","journal-title":"Ann Intern Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0675","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/oxfordjournals.aje.a009781","article-title":"Relation of calcium, vitamin D, and dairy food intake to ischemic heart disease mortality among postmenopausal women","volume":"149","author":"Bostick","year":"1999","journal-title":"Am J Epidemiol."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0680","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1210\/jc.2007-1466","article-title":"Effects of calcium and vitamin D supplementation on hip bone mineral density and calcium-related analytes in elderly ambulatory Australian women: a five-year randomized controlled trial","volume":"93","author":"Zhu","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0685","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1359\/jbmr.080327","article-title":"Randomized controlled trial of the effects of calcium with or without vitamin D on bone structure and bone-related chemistry in elderly women with vitamin D insufficiency","volume":"23","author":"Zhu","year":"2008","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0690","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1210\/jc.2013-1516","article-title":"Calcium and vitamin D intake and mortality: results from the Canadian Multicentre Osteoporosis Study (CaMos)","volume":"98","author":"Langsetmo","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0695","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1359\/jbmr.070905","volume":"23","author":"Silverman","year":"2008","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0700","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMcp1210380","article-title":"Clinical practice. Calcium supplements and fracture prevention","volume":"369","author":"Bauer","year":"2013","journal-title":"N Engl J Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0705","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00198-012-2224-2","article-title":"Health risks and benefits from calcium and vitamin D supplementation: Women\u2019s Health Initiative clinical trial and cohort study","volume":"24","author":"Prentice","year":"2013","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0710","first-page":"895","article-title":"Calcium supplements: bad for the heart?","volume":"98","author":"Reid","year":"2012","journal-title":"Heart (British Cardiac Society)."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0715","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.3945\/ajcn.111.015032","article-title":"Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women\u2019s Health Initiative (WHI) limited-access data set","volume":"94","author":"Bolland","year":"2011","journal-title":"Am J Clin Nutr."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0720","doi-asserted-by":"crossref","first-page":"691","DOI":"10.7326\/0003-4819-158-9-201305070-00603","article-title":"Vitamin D and calcium supplementation to prevent fractures in adults: U.S. Preventive Services Task Force recommendation statement","volume":"158","author":"Moyer","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.4158\/GL-2020-0524SUPPL_bb0725","first-page":"1","article-title":"Dietary intake of vitamins, minerals, and fiber of persons ages 2 months and over in the United States: Third National Health and Nutrition Examination Survey, Phase 1, 1988-91","author":"Alaimo","year":"1994","journal-title":"Adv Data."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0730","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s12011-014-9936-4","article-title":"Effect of water-soluble silicon supplementation on bone status and balance of calcium and magnesium in male mice","volume":"158","author":"Kim","year":"2014","journal-title":"Biol Trace Elem Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0735","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1080\/07315724.1994.10718439","article-title":"Effect of magnesium on the intestinal absorption of calcium in man","volume":"13","author":"Spencer","year":"1994","journal-title":"J Am Coll Nutr."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0740","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1345\/aph.1G028","article-title":"Effect of vitamin A on fracture risk","volume":"39","author":"Jackson","year":"2005","journal-title":"Ann Pharmacother."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0745","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00223-002-2084-4","article-title":"Vitamin K1 supplementation retards bone loss in postmenopausal women between 50 and 60 years of age","volume":"73","author":"Braam","year":"2003","journal-title":"Calcif Tissue Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0750","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1001\/jama.285.11.1482","article-title":"Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial","volume":"285","author":"Alexandersen","year":"2001","journal-title":"JAMA."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0755","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/ajcn\/79.2.326","article-title":"The effects of phytoestrogen isoflavones on bone density in women: a double-blind, randomized, placebo-controlled trial","volume":"79","author":"Atkinson","year":"2004","journal-title":"Am J Clin Nutr."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0760","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/01.GME.0000097845.95550.71","article-title":"The effect of soy protein isolate on bone metabolism","volume":"11","author":"Gallagher","year":"2004","journal-title":"Menopause."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0765","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00198-006-0109-y","article-title":"Coffee, tea and caffeine consumption in relation to osteoporotic fracture risk in a cohort of Swedish women","volume":"17","author":"Hallstrom","year":"2006","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0770","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/oxfordjournals.aje.a115709","article-title":"Caffeine and the risk of hip fracture: the Framingham Study","volume":"132","author":"Kiel","year":"1990","journal-title":"Am J Epidemiol."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0775","first-page":"280","article-title":"Coffee-associated osteoporosis offset by daily milk consumption","volume":"271","author":"Barrett-Connor","year":"1994","journal-title":"The Rancho Bernardo Study. JAMA."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0780","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1297-319X(01)00295-0","article-title":"Protein intake and bone disorders in the elderly","volume":"68","author":"Rizzoli","year":"2001","journal-title":"Joint Bone Spine."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0785","doi-asserted-by":"crossref","first-page":"801","DOI":"10.7326\/0003-4819-128-10-199805150-00002","article-title":"Protein supplements increase serum insulin-like growth factor-I levels and attenuate proximal femur bone loss in patients with recent hip fracture. A randomized, double-blind, placebo-controlled trial","volume":"128","author":"Sch\u00fcrch","year":"1998","journal-title":"Ann Intern Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0790","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00198-004-1734-y","article-title":"Alcohol intake as a risk factor for fracture","volume":"16","author":"Kanis","year":"2005","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0795","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00198-009-0981-3","article-title":"The role of cigarette smoking and statins in the development of postmenopausal osteoporosis: a pilot study utilizing the Marshfield Clinic Personalized Medicine Cohort","volume":"21","author":"Giampietro","year":"2010","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0800","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1001\/archinte.1976.03630030032007","article-title":"Osteoporosis of the slender smoker. Vertebral compression fractures and loss of metacarpal cortex in relation to postmenopausal cigarette smoking and lack of obesity","volume":"136","author":"Daniell","year":"1976","journal-title":"Arch Intern Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0805","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00198-004-1640-3","article-title":"Smoking and fracture risk: a meta-analysis","volume":"16","author":"Kanis","year":"2005","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0810","doi-asserted-by":"crossref","first-page":"M599","DOI":"10.1093\/gerona\/57.9.M599","article-title":"Exercise and lumbar spine bone mineral density in postmenopausal women: a meta-analysis of individual patient data","volume":"57","author":"Kelley","year":"2002","journal-title":"J Gerontol A Biol Sci Med Sci."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0815","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1006\/pmed.2002.1017","article-title":"Application of a falls prevention program for older people to primary health care practice","volume":"34","author":"Gardner","year":"2002","journal-title":"Prev Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0820","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1046\/j.1532-5415.2002.50218.x","article-title":"Preventing injuries in older people by preventing falls: a metaanalysis of individual-level data","volume":"50","author":"Robertson","year":"2002","journal-title":"J Am Geriatr Soc."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0825","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s001980050109","article-title":"The effect of exercise training programs on bone mass: a meta-analysis of published controlled trials in pre-and postmenopausal women","volume":"9","author":"Wolff","year":"1999","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0830","doi-asserted-by":"crossref","first-page":"188.e113","DOI":"10.1016\/j.jamda.2011.04.022","article-title":"Effectiveness of intervention programs in preventing falls: a systematic review of recent 10 years and metaanalysis","volume":"13","author":"Choi","year":"2012","journal-title":"J Am Med Dir Assoc"},{"key":"10.4158\/GL-2020-0524SUPPL_bb0835","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1111\/j.1532-5415.2008.02014.x","article-title":"Effective exercise for the prevention of falls: a systematic review and meta-analysis","volume":"56","author":"Sherrington","year":"2008","journal-title":"J Am Geriatr Soc."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0840","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/1471-2474-13-177","article-title":"Effects of ground and joint reaction force exercise on lumbar spine and femoral neck bone mineral density in postmenopausal women: a meta-analysis of randomized controlled trials","volume":"13","author":"Kelley","year":"2012","journal-title":"BMC Musculoskel Disord."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0845","series-title":"Falls & related injuries among older Canadians. Canada.2010","article-title":"Prepared on behalf of the Public Health Agency of Canada, Division of Aging and Seniors","author":"Scott","year":"2011"},{"key":"10.4158\/GL-2020-0524SUPPL_bb0850","first-page":"CD007146","article-title":"Interventions for preventing falls in older people living in the community","author":"Gillespie","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.4158\/GL-2020-0524SUPPL_bb0855","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s40279-013-0041-1","article-title":"The importance of trunk muscle strength for balance, functional performance, and fall prevention in seniors: a systematic review","volume":"43","author":"Granacher","year":"2013","journal-title":"Sports Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0860","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1056\/NEJM198812293192604","article-title":"Risk factors for falls among elderly persons living in the community","volume":"319","author":"Tinetti","year":"1988","journal-title":"N Engl J Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0865","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1053\/apmr.2001.24893","article-title":"Gait variability and fall risk in community-living older adults: a 1-year prospective study","volume":"82","author":"Hausdorff","year":"2001","journal-title":"Arch Phys Med Rehabil."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0875","first-page":"1221","article-title":"Fatalities and injuries from falls among older adults-United States, 1993-2003 and 2001-2005","volume":"55","year":"2006","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.4158\/GL-2020-0524SUPPL_bb0880","doi-asserted-by":"crossref","first-page":"582","DOI":"10.2519\/jospt.2010.3239","article-title":"Predictors of falls in women with and without osteoporosis","volume":"40","author":"da Silva","year":"2010","journal-title":"J Orthop Sports Phys Ther."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0885","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jbspin.2014.01.020","article-title":"Usefulness of bone density measurement in fallers","volume":"81","author":"Blain","year":"2014","journal-title":"Joint Bone Spine."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0890","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jbspin.2012.02.014","article-title":"2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis","volume":"79","author":"Briot","year":"2012","journal-title":"Joint Bone Spine."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0895","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1046\/j.1532-5415.2003.51404.x","article-title":"Dementia as a risk factor for falls and fall injuries among nursing home residents","volume":"51","author":"van Doorn","year":"2003","journal-title":"J Am Geriatr Soc."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0900","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1471-2318-14-15","article-title":"Multiple component interventions for preventing falls and fall-related injuries among older people: systematic review and meta-analysis","volume":"14","author":"Goodwin","year":"2014","journal-title":"BMC Geriatr."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0905","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s00198-012-2248-7","article-title":"Effects of exercise on fracture reduction in older adults: a systematic review and meta-analysis","volume":"24","author":"Kemmler","year":"2013","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0910","doi-asserted-by":"crossref","first-page":"b3692","DOI":"10.1136\/bmj.b3692","article-title":"Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials","volume":"339","author":"Bischoff-Ferrari","year":"2009","journal-title":"BMJ."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0915","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1001\/jama.291.16.1999","article-title":"Effect of vitamin D on falls: a meta-analysis","volume":"291","author":"Bischoff-Ferrari","year":"2004","journal-title":"JAMA."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0920","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1001\/jamainternmed.2015.0225","article-title":"Exercise and vitamin D in fall prevention among older women: a randomized clinical trial","volume":"175","author":"Uusi-Rasi","year":"2015","journal-title":"JAMA Intern Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0925","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1177\/0269215509339002","article-title":"Effects of exercise programmes on quality of life in osteoporotic and osteopenic postmenopausal women: a systematic review and meta-analysis","volume":"23","author":"Li","year":"2009","journal-title":"Clin Rehabil."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0930","first-page":"1535","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Fracture Intervention Trial Research Group. Lancet."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0935","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0940","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0945","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0950","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00198-004-1698-y","article-title":"Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture","volume":"16","author":"Kanis","year":"2005","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0955","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0002-9343(00)00490-3","article-title":"A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group","volume":"109","author":"Chesnut","year":"2000","journal-title":"Am J Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0960","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0965","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0970","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0975","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid in reducing clinical fracture and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0980","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","article-title":"Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group","volume":"85","author":"Black","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0985","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N Engl J Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0990","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1359\/JBMR.050313","article-title":"Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study","volume":"20","author":"Miller","year":"2005","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb0995","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/ard.2005.044958","article-title":"Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study","volume":"65","author":"Reginster","year":"2006","journal-title":"Ann Rheum Dis."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1000","first-page":"488","volume":"35","year":"2008","journal-title":"J Rheumatol"},{"key":"10.4158\/GL-2020-0524SUPPL_bb1005","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1010","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1015","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S8756-3282(02)00946-8","article-title":"Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience","volume":"32","author":"Sorensen","year":"2003","journal-title":"Bone."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1020","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women\u2019s Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1025","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1030","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00198-008-0559-5","article-title":"Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA","volume":"19","author":"Dawson-Hughes","year":"2008","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00198-009-1033-8","article-title":"The effects of a FRAX revision for the USA","volume":"21","author":"Kanis","year":"2010","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1040","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00198-009-1032-9","article-title":"Updated fracture incidence rates for the US version of FRAX","volume":"21","author":"Ettinger","year":"2010","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1045","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00198-007-0550-6","article-title":"Cost-effective osteoporosis treatment thresholds: the United States perspective","volume":"19","author":"Tosteson","year":"2008","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1050","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N Engl J Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1055","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s00198-011-1856-y","article-title":"The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures","volume":"23","author":"Hadji","year":"2012","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1060","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with sever osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2017","journal-title":"Lancet."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1065","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"New Engl J Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1070","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00198-017-3976-5","article-title":"Imminent fracture risk","volume":"28","author":"Roux","year":"2017","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1075","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00198-016-3868-0","article-title":"Imminent risk of fracture after fracture","volume":"28","author":"Johansson","year":"2017","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1080","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11657-016-0280-5","article-title":"Predicting imminent risk for fracture in patients aged 50 or older with osteoporosis using US claims data","volume":"11","author":"Bonafede","year":"2016","journal-title":"Arch Osteoporos."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1085","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.bone.2017.08.018","article-title":"Determinants of short term fracture risk in patients with a recent history of low-trauma non-vertebral fracture","volume":"105","author":"Deloumeau","year":"2017","journal-title":"Bone."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1090","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/jbmr.556","article-title":"FRAX underestimates fracture risk in patients with diabetes","volume":"27","author":"Giangregorio","year":"2012","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1095","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1001\/jama.2011.715","article-title":"Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes","volume":"305","author":"Schwartz","year":"2011","journal-title":"JAMA."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1100","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jocd.2016.04.001","article-title":"Trabecular Bone Score (TBS) and TBS-adjusted Fracture Risk Assessment Tool are potential supplementary tools for the discrimination of morphometric vertebral fractures in postmenopausal women with type 2 diabetes","volume":"19","author":"Choi","year":"2016","journal-title":"J Clin Densitom."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1105","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s00223-016-0191-x","article-title":"DXA-based measurements in diabetes: can they predict fracture risk?","volume":"100","author":"Schacter","year":"2017","journal-title":"Calcif Tissue Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1110","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1115","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1120","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199007123230201","article-title":"Intermittent cyclical etidronate treatment of postmenopausal osteoporosis","volume":"323","author":"Watts","year":"1990","journal-title":"N Engl J Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1125","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/jbmr.3051","article-title":"Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis","volume":"32","author":"Cosman","year":"2017","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1130","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1210\/jc.2007-2814","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women","volume":"93","author":"Bone","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1135","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1359\/jbmr.0301202","article-title":"Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis","volume":"19","author":"McClung","year":"2004","journal-title":"J Bonoe Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1140","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1001\/archinte.160.4.517","article-title":"Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial","volume":"160","author":"Bauer","year":"2000","journal-title":"Arch Intern Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1145","series-title":"Atelvia (risedronate sodium) delayed-release tablets","year":"2015"},{"key":"10.4158\/GL-2020-0524SUPPL_bb1150","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder CKD-MBD","year":"2009","journal-title":"Kidney Int Suppl"},{"key":"10.4158\/GL-2020-0524SUPPL_bb1155","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1046\/j.1365-2141.2002.03835_4.x","article-title":"Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions","volume":"119","author":"Jones","year":"2002","journal-title":"Br J Haematol."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1160","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM200310233491721","article-title":"Renal failure with the use of zoledronic acid","volume":"349","author":"Chang","year":"2003","journal-title":"N Engl J Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1165","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/BF02556671","article-title":"The acute-phase response after bisphosphonate administration","volume":"41","author":"Adami","year":"1987","journal-title":"Calcif Tissue Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1170","first-page":"346","article-title":"Alendronate and risedronate: reports of severe bone, joint, and muscle pain","volume":"165","author":"Wysowski","year":"2005","journal-title":"Arch Intern Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1175","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/jama.2010.1098","article-title":"Exposure to oral bisphosphonates and risk of esophageal cancer","volume":"304","author":"Cardwell","year":"2010","journal-title":"JAMA."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1180","doi-asserted-by":"crossref","first-page":"c4444","DOI":"10.1136\/bmj.c4444","article-title":"Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort","volume":"341","author":"Green","year":"2010","journal-title":"BMJ."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1185","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.amjmed.2012.06.023","article-title":"Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday","volume":"126","author":"McClung","year":"2013","journal-title":"Am J Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1190","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1195","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1210\/jc.2016-1801","article-title":"Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates","volume":"101","author":"Miller","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1200","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1205","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00198-012-2052-4","article-title":"Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial","volume":"24","author":"McClung","year":"2013","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1210","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1210\/jc.2013-1597","article-title":"The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension","volume":"98","author":"Bone","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1215","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00198-011-1755-2","article-title":"Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?","volume":"23","author":"Watts","year":"2012","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1220","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM Trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1225","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1230","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/jc.2016-3170","article-title":"Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical case reports","volume":"102","author":"Lamy","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1235","series-title":"Fortical calcitonin-salmon [rDNA origin] Nasal spray for intranasal use [package insert]","year":"2014"},{"key":"10.4158\/GL-2020-0524SUPPL_bb1240","series-title":"Miacalcin (calcitonin-salmon) for injection and nasal spray [package insert]","year":"2014"},{"key":"10.4158\/GL-2020-0524SUPPL_bb1245","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/B978-0-12-801238-3.95758-1","article-title":"Physiology of calcitonin and its therapeutic uses","author":"Wimalawansa","year":"2018","journal-title":"Encyclopedia of Endocrine Diseases: Second Edition."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1250","first-page":"205","article-title":"Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures","volume":"11","author":"Pun","year":"1989","journal-title":"Clin Ther."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1255","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10067-006-0228-z","article-title":"The effect of calcitonin on beta-endorphin levels in postmenopausal osteoporotic patients with back pain","volume":"26","author":"Ofluoglu","year":"2007","journal-title":"Clin Rheumatol."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1260","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s10067-005-0159-0","article-title":"Comparison of the analgesic efficacy of pamidronate and synthetic human calcitonin in osteoporotic vertebral fractures: a double-blind controlled study","volume":"25","author":"Laroche","year":"2006","journal-title":"Clin Rheumatol."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1265","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/17453674.1997.11744761","article-title":"Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study","volume":"275","author":"Lyritis","year":"1997","journal-title":"Acta Orthop Scand Suppl."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1270","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/00002508-199912000-00004","article-title":"Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, placebo-controlled clinical study","volume":"15","author":"Lyritis","year":"1999","journal-title":"Clin J Pain."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1275","series-title":"Questions and answers: changes to the indicated population for miacalcin (calcitonin-salmon)","author":"U.S. Food and Drug Administration","year":"2014"},{"key":"10.4158\/GL-2020-0524SUPPL_bb1280","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00198-015-3339-z","article-title":"Does salmon calcitonin cuase cancer? A review and meta-analysis","volume":"27","author":"Wells","year":"2016","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1285","unstructured":"Wells G Evista raloxifene hydrochloride tablet for oral use [package insert]. Eli Lilly and Co, 2011."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1290","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial","volume":"295","author":"Vogel","year":"2006","journal-title":"JAMA."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1295","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"N Engl J Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1300","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199712043372301","article-title":"Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women","volume":"337","author":"Delmas","year":"1997","journal-title":"N Engl J Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1305","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrd3299","article-title":"Emerging therapeutic opportunities for skeletal restoration","volume":"10","author":"Kawai","year":"2011","journal-title":"Nat Rev Drug Discov."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1310","doi-asserted-by":"crossref","first-page":"E189","DOI":"10.1210\/jc.2013-1707","article-title":"Effects of bazedoxifene\/conjugated estrogens on the endometrium and bone: a randomized trial","volume":"99","author":"Pinkerton","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1315","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.fertnstert.2009.02.093","article-title":"Efficacy of tissue-selective estrogen complex of bazedoxifene\/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women","volume":"92","author":"Lindsey","year":"2009","journal-title":"Fertil Steril."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1320","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/CIA.S15711","article-title":"Efficacy and safety of bazedonxifene for postmenopausal osteoporosis","volume":"6","author":"Kawate","year":"2011","journal-title":"Clin Interv Aging."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1325","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1359\/jbmr.080710","article-title":"Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial","volume":"23","author":"Silverman","year":"2008","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1330","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/GME.0000000000000419","article-title":"A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture","volume":"22","author":"Palacios","year":"2015","journal-title":"Menopause (New York, NY)"},{"key":"10.4158\/GL-2020-0524SUPPL_bb1335","doi-asserted-by":"crossref","first-page":"5064725","DOI":"10.1155\/2017\/5064725","article-title":"The tissue-selective estrogen complex (bazedoxifene\/conjugated estrogens) for the treatment of menopause","volume":"2017","author":"Lello","year":"2017","journal-title":"Int J Endocrinol."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1340","series-title":"Premarin (conjugated estrogens) tablets, USP for oral use [package insert]","year":"2014"},{"key":"10.4158\/GL-2020-0524SUPPL_bb1345","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.290.13.1729","article-title":"Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women\u2019s Health Initiative randomized trial","volume":"290","author":"Cauley","year":"2003","journal-title":"JAMA."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1350","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1359\/jbmr.060312","article-title":"Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women\u2019s health initiative randomized trial","volume":"21","author":"Jackson","year":"2006","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1355","series-title":"Tymlos abaloparatide injection, for subcutaneous use","year":"2017"},{"key":"10.4158\/GL-2020-0524SUPPL_bb1360","series-title":"Forteo (teriparatide [rDNA origin] injection) for subcutaneous use [package insert]","year":"2012"},{"key":"10.4158\/GL-2020-0524SUPPL_bb1365","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1370","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1359\/jbmr.081256","article-title":"Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment","volume":"24","author":"Watts","year":"2009","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1375","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/01926230252929882","article-title":"Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety","volume":"30","author":"Vahle","year":"2002","journal-title":"Toxicol Pathol."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1380","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/01926230490462138","article-title":"Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose","volume":"32","author":"Vahle","year":"2004","journal-title":"Toxicol Pathol."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1385","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1359\/jbmr.061111","article-title":"Osteosarcoma and teriparatide?","volume":"22","author":"Harper","year":"2007","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1390","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00198-009-1004-0","article-title":"Of mice and men: divergent risks of teriparatide-induced osteosarcoma","volume":"21","author":"Subbiah","year":"2010","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1395","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1001\/archinte.164.18.2024","article-title":"Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis","volume":"164","author":"Lindsay","year":"2004","journal-title":"Arch Intern Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1400","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"N Engl J Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1405","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1410","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis","volume":"103","author":"Bone","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1415","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1420","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/jbmr.2932","article-title":"Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass","volume":"32","author":"Genant","year":"2017","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1425","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1430","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1210\/jc.2017-02163","article-title":"A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis","volume":"103","author":"Lewiecki","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1435","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/jbmr.5650091216","article-title":"Femoral bone loss progresses with age: a longitudinal study in women over age 65","volume":"9","author":"Greenspan","year":"1994","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1440","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/jbmr.5650100806","article-title":"Vitamin D status and sex hormone binding globulin: determinants of bone turnover and bone mineral density in elderly women","volume":"10","author":"Ooms","year":"1995","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1445","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/01.GME.0000123641.76105.B5","article-title":"Changes in bone density and turnover after alendronate or estrogen withdrawal","volume":"11","author":"Wasnich","year":"2004","journal-title":"Menopause."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1450","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1210\/jc.2002-020727","article-title":"Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers","volume":"87","author":"Gallagher","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1455","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa1107142","article-title":"Bone-density testing interval and transition to osteoporosis in older women","volume":"366","author":"Gourlay","year":"2012","journal-title":"N Engl J Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1460","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00198-008-0661-8","article-title":"Assessing response to osteoporosis therapy","volume":"19","author":"Lewiecki","year":"2008","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1465","first-page":"S367","article-title":"How common is loss of bone mineral density in elderly clinical practice patients receiving oral bisphosphonate therapy for osteoporosis","volume":"17","author":"Lewiecki","year":"2002","journal-title":"J Bone Miner Res."},{"issue":"suppl","key":"10.4158\/GL-2020-0524SUPPL_bb1470","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1385\/JCD:5:3S:S29","article-title":"What is the role of serial bone mineral density measurements in patient management?","volume":"5","author":"Lenchik","year":"2002","journal-title":"J Clin Densitom."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1475","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1385\/JCD:8:4:371","article-title":"Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry","volume":"8","author":"Baim","year":"2005","journal-title":"J Clin Densitom."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1480","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s001980070070","article-title":"Follow-up of individual patients on two DXA scanners of the same manufacturer","volume":"11","author":"Kolta","year":"2000","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1485","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026267","article-title":"Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a meta-analysis of randomized controlled trials","volume":"6","author":"Shen","year":"2011","journal-title":"PLoS One."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1490","doi-asserted-by":"crossref","first-page":"32475","DOI":"10.1074\/jbc.M113.514034","article-title":"Artificial sweeteners stimulate adipogenesis and suppress lipolysis independently of sweet taste receptors","volume":"288","author":"Simon","year":"2013","journal-title":"J Biol Chem."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1495","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jocd.2007.12.008","article-title":"Vertebral fracture assessment: the 2007 ISCD official positions","volume":"11","author":"Schousboe","year":"2008","journal-title":"J Clin Densitom."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1500","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jocd.2013.08.004","article-title":"Executive summary of the 2013 International Society for Clinical Densitometry position development conference on bone densitometry","volume":"16","author":"Schousboe","year":"2013","journal-title":"J Clin Densitom."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1505","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/1529-0131(199906)42:6<1246::AID-ANR22>3.0.CO;2-U","article-title":"Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group","volume":"42","author":"Hochberg","year":"1999","journal-title":"Arthritis Rheum."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1510","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1385\/JCD:7:3:255","article-title":"Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk","volume":"7","author":"Watts","year":"2004","journal-title":"J Clin Densitom."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1515","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1007\/s00198-004-1770-7","article-title":"Risk of fracture among women who lose bone density during treatment with alendronate","volume":"16","author":"Chapurlat","year":"2005","journal-title":"The Fracture Intervention Trial. Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1520","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1359\/jbmr.090207","article-title":"Hip fracture patients at risk of second hip fracture: a nationwide population-based cohort study of 169,145 cases during 1977-2001","volume":"24","author":"Ryg","year":"2009","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1525","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1359\/jbmr.1999.14.5.821","article-title":"Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group","volume":"14","author":"Black","year":"1999","journal-title":"J Bone Mineral Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1530","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1210\/jc.2004-0826","article-title":"Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures","volume":"90","author":"Gallagher","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1535","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1210\/jc.2012-3680","article-title":"Treat-to-target for osteoporosis: is now the time?","volume":"98","author":"Lewiecki","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1540","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/jbmr.1854","article-title":"Goal-directed treatment of osteoporosis","volume":"28","author":"Cummings","year":"2013","journal-title":"J Bone Miner Res."},{"issue":"Suppl 2","key":"10.4158\/GL-2020-0524SUPPL_bb1545","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S1098-3597(03)90043-3","article-title":"Mechanisms of osteoporosis therapy: a bone strength perspective","author":"Bouxsein","year":"2003","journal-title":"Clin Cornerstone"},{"key":"10.4158\/GL-2020-0524SUPPL_bb1550","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0002-9343(03)00362-0","article-title":"Early discontinuation of treatment for osteoporosis","volume":"115","author":"Tosteson","year":"2003","journal-title":"Am J Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1555","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Ann Intern Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1560","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1056\/NEJMp068157","article-title":"Osteonecrosis of the jaw--do bisphosphonates pose a risk?","volume":"355","author":"Bilezikian","year":"2006","journal-title":"N Engl J Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1565","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1570","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1575","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1210\/jc.2018-01965","article-title":"Invasive oral procedures and events in postmenopausal women with osteoporosis treated with denosumab for up to 10 years","volume":"104","author":"Watts","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1580","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J Oral Maxillofac Surg."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1585","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00198-008-0805-x","article-title":"Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study","volume":"20","author":"Lenart","year":"2009","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1590","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1595","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1056\/NEJMc1403799","article-title":"Risk of atypical femoral fracture during and after bisphosphonate use","volume":"371","author":"Schilcher","year":"2014","journal-title":"N Engl J Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1600","doi-asserted-by":"crossref","first-page":"R81","DOI":"10.1530\/EJE-17-1002","article-title":"Management of endocrine disease: Atypical femoral fractures: risks and benefits of long-term treatment of osteoporosis with anti-resorptive therapy","volume":"178","author":"Adler","year":"2018","journal-title":"Eur J Endocrinol."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1605","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMcp1513724","article-title":"Clinical Practice. Postmenopausal Osteoporosis","volume":"374","author":"Black","year":"2016","journal-title":"N Engl J Med"},{"key":"10.4158\/GL-2020-0524SUPPL_bb1610","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/jbmr.253","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research","volume":"25","author":"Shane","year":"2010","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1615","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/jbmr.288","article-title":"Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort","volume":"26","author":"Kim","year":"2011","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1620","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/jbmr.2767","article-title":"Mortality after atypical femoral fractures: a cohort study","volume":"31","author":"Kharazmi","year":"2016","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1625","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.bone.2012.10.006","article-title":"Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy","volume":"52","author":"Chiang","year":"2013","journal-title":"Bone."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1630","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00774-014-0617-3","article-title":"Healting of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: a comparison between treatment with and without teriparatide","volume":"33","author":"Miyakoshi","year":"2015","journal-title":"J Bone Miner Metab."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1635","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/jbmr.3081","article-title":"Responses to treatment with teriparatide in patients with atypical femur fractures previously treated with bisphosphonates","volume":"32","author":"Watts","year":"2017","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1640","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a Task Force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1645","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/jbmr.11","article-title":"Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial","volume":"25","author":"Schwartz","year":"2010","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1650","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1210\/jc.2014-1971","article-title":"Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?","volume":"99","author":"Cosman","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1655","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/jbmr.2442","article-title":"The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"30","author":"Black","year":"2015","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1660","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1665","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1007\/s00198-017-4215-9","article-title":"Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk","volume":"28","author":"Mignot","year":"2017","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1670","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4158\/EP171975.OR","article-title":"Osteoporotic fractures during bisphosphonate drug holiday","volume":"24","author":"Bindon","year":"2018","journal-title":"Endocr Pract."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1675","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","article-title":"Bisphosphonates: the first 40 years","volume":"49","author":"Russell","year":"2011","journal-title":"Bone."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1680","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1046\/j.1365-2265.2002.01536.x","article-title":"Combination therapy for postmenopausal osteoporosis","volume":"56","author":"Compston","year":"2002","journal-title":"Clin Endocrinol."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1685","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1690","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1210\/jc.2013-4440","article-title":"Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial","volume":"99","author":"Leder","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1695","first-page":"2129","article-title":"Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate","volume":"85","author":"Rittmaster","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1700","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1359\/JBMR.050714","article-title":"Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial","volume":"20","author":"Deal","year":"2005","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1705","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N Engl J Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1710","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1715","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","article-title":"Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women","volume":"23","author":"Freemantle","year":"2012","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1720","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/01.med.0000436194.10599.94","article-title":"Postmenopausal osteoporosis","volume":"20","author":"Diab","year":"2013","journal-title":"Curr Opin Endocrinol Diabetes Obes."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1725","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM Trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1730","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1210\/jc.2007-0711","article-title":"Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis","volume":"93","author":"Boonen","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1735","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa0900563","article-title":"A randomized trial of vertebroplasty for osteoporotic spinal fractures","volume":"361","author":"Kallmes","year":"2009","journal-title":"N Engl J Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1740","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1056\/NEJMoa0900429","article-title":"A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures","volume":"361","author":"Buchbinder","year":"2009","journal-title":"N Engl J Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1745","doi-asserted-by":"crossref","first-page":"d3952","DOI":"10.1136\/bmj.d3952","article-title":"Effectiveness of vertebroplasty using individual patient data from two randomised placebo controlled trials: meta-analysis","volume":"343","author":"Staples","year":"2011","journal-title":"BMJ."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1750","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/jbmr.2157","article-title":"Two-year results of a randomized placebo-controlled trial of vertebroplasty for acute osteoporotic vertebral fractures","volume":"29","author":"Kroon","year":"2014","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1755","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/jbmr.1564","article-title":"Effect of vertebroplasty on pain relief, quality of life, and the incidence of new vertebral fractures: a 12-month randomized follow-up, controlled trial","volume":"27","author":"Blasco","year":"2012","journal-title":"J Bone Miner Res."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1760","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.3174\/ajnr.A2148","article-title":"Percutaneous vertebroplasty is not a risk factor for new osteoporotic compression fractures: results from VERTOS II","volume":"31","author":"Klazen","year":"2010","journal-title":"Am J Neuroradiol."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1765","first-page":"715","article-title":"Safety of balloon kyphoplasty in the treatment of osteoporotic vertebral compression fractures in Europe: a meta-analysis of randomized controlled trials","volume":"24","author":"B\u00f3uza","year":"2015","journal-title":"Eur Spine J."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1770","first-page":"992","article-title":"Do the hospitalized patients with osteoporotic fractures require endocrinologists\u2019 help?","volume":"35","author":"Aghamirsalim","year":"2012","journal-title":"J Endocrinol Invest."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1775","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11657-013-0167-7","article-title":"Effect of a dedicated osteoporosis health professional on screening and treatment in outpatients presenting with acute low trauma non-hip fracture: a systematic review","volume":"9","author":"Bell","year":"2014","journal-title":"Arch Osteoporos."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1780","series-title":"National Service Center Publications (NSCEP)","article-title":"Community Environmental Monitoring Program 25th Anniversary Annual Workshop","author":"Radonich","year":"2006"},{"key":"10.4158\/GL-2020-0524SUPPL_bb1785","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1177\/0272989X9901900411","article-title":"How should effectiveness of risk communication to aid patients\u2019 decisions be judged? A review of the literature","volume":"19","author":"Edwards","year":"1999","journal-title":"Med Decis Making."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1790","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.2003.05.057","article-title":"Shared treatment decision making: what does it mean to physicians?","volume":"21","author":"Charles","year":"2003","journal-title":"J Clin Oncol."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1795","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0277-9536(99)00145-8","article-title":"Decision-making in the physician-patient encounter: revisiting the shared treatment decision-making model","volume":"49","author":"Charles","year":"1999","journal-title":"Social science & medicine (1982)"},{"key":"10.4158\/GL-2020-0524SUPPL_bb1800","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0277-9536(96)00221-3","article-title":"Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango)","volume":"44","author":"Charles","year":"1997","journal-title":"Soc Sci Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1805","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jocd.2010.06.005","article-title":"Risk communication and shared decision making in the care of patients with osteoporosis","volume":"13","author":"Lewiecki","year":"2010","journal-title":"J Clin Densitom."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1810","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s001980070097","article-title":"Study subjects and ordinary patients","volume":"11","author":"Dowd","year":"2000","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1815","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2753.2005.00596.x","article-title":"A systematic review on communicating with patients about evidence","volume":"12","author":"Trevena","year":"2006","journal-title":"J Eval Clin Pract."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1820","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/01421590802350776","article-title":"Preparing medical students to become attentive listeners","volume":"31","author":"Boudreau","year":"2009","journal-title":"Med Teach."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1825","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.3399\/bjgp11X588439","article-title":"Risk communication methods in hip fracture prevention: a randomised trial in primary care","volume":"61","author":"Hudson","year":"2011","journal-title":"Br J Gen Pract."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1830","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.amjmed.2011.01.013","article-title":"Use of a decision aid to improve treatment decisions in osteoporosis: the osteoporosis choice randomized trial","volume":"124","author":"Montori","year":"2011","journal-title":"Am J Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1835","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1210\/jc.2003-030501","article-title":"The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial","volume":"89","author":"Clowes","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1840","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00198-008-0698-8","article-title":"Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience","volume":"20","author":"Briot","year":"2009","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1845","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1010650","article-title":"Bisphosphonate use and atypical fractures of the femoral shaft","volume":"364","author":"Schilcher","year":"2011","journal-title":"N Engl J Med."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1850","author":"Hansen"},{"key":"10.4158\/GL-2020-0524SUPPL_bb1855","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s001980170112","article-title":"The burden of osteoporotic fractures: a method for setting intervention thresholds","volume":"12","author":"Kanis","year":"2001","journal-title":"Osteoporos Int."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1860","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/pds.822","article-title":"Risk of anaphylaxis in a hospital population in relation to the use of various drugs: an international study","volume":"12","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"10.4158\/GL-2020-0524SUPPL_bb1865","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.14219\/jada.archive.2006.0355","article-title":"Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations","volume":"137","year":"2006","journal-title":"J Am Dent Assoc."}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20428277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20428277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:08:00Z","timestamp":1761516480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20428277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":371,"alternative-id":["S1530891X20428277"],"URL":"https:\/\/doi.org\/10.4158\/gl-2020-0524suppl","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"American Association of Clinical Endocrinologists\/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis\u20142020 Update","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/GL-2020-0524SUPPL","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}